DexCom (NASDAQ:DXCM) Price Target Raised to $90.00

DexCom (NASDAQ:DXCM) had its price objective upped by Mizuho from $78.00 to $90.00 in a report released on Friday morning, MarketBeat Ratings reports. Mizuho currently has an outperform rating on the medical device company’s stock.

Several other research firms have also recently commented on DXCM. BTIG Research reaffirmed a “buy” rating and issued a $85.00 target price on shares of DexCom in a research note on Friday. Morgan Stanley restated an “overweight” rating on shares of DexCom in a report on Monday, January 12th. Robert W. Baird set a $82.00 target price on DexCom in a research note on Friday, October 31st. Truist Financial reiterated a “buy” rating and set a $82.00 target price (down from $94.00) on shares of DexCom in a research report on Monday, November 3rd. Finally, Evercore started coverage on DexCom in a report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $85.27.

DexCom Trading Up 7.6%

Shares of DXCM stock opened at $70.02 on Friday. The firm has a 50-day moving average price of $69.03 and a 200 day moving average price of $69.47. DexCom has a twelve month low of $54.11 and a twelve month high of $93.25. The company has a market capitalization of $26.95 billion, a price-to-earnings ratio of 33.34, a PEG ratio of 1.25 and a beta of 1.49. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period last year, the company earned $0.45 EPS. Research analysts forecast that DexCom will post 2.03 earnings per share for the current fiscal year.

Institutional Trading of DexCom

A number of institutional investors have recently modified their holdings of DXCM. Andra AP fonden acquired a new stake in DexCom during the 2nd quarter worth approximately $26,000. Twin Peaks Wealth Advisors LLC acquired a new position in DexCom during the second quarter valued at approximately $26,000. SJS Investment Consulting Inc. lifted its position in DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after buying an additional 384 shares in the last quarter. Financial Consulate Inc. purchased a new stake in DexCom during the third quarter worth approximately $29,000. Finally, CVA Family Office LLC increased its position in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom News Summary

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q4 results beat expectations: DexCom reported $0.68 EPS vs. $0.65 consensus and $1.26B in revenue (≈13% YoY); management reiterated 2026 guidance, supporting near-term outlook. Dexcom beats quarterly estimates
• Positive Sentiment: G7 15‑day sensor rollout and margin gains cited as growth drivers — management pointed to product adoption and improving margins as catalysts for revenue and profitability expansion. G7 rollout drives growth
• Positive Sentiment: Mizuho raised its price target to $90 (outperform), signaling confidence in longer‑term upside and helping buy‑side sentiment. Mizuho price target raise
• Positive Sentiment: BTIG reaffirmed a Buy rating with an $85 target, adding to analyst support that underpins the rally. BTIG reaffirmation
• Positive Sentiment: Product/AI initiative — the Stelo AI upgrade aims to deepen consumer metabolic-health engagement, which could expand recurring usage and ARPU over time. Stelo AI upgrade
• Neutral Sentiment: Analyst activity is mixed overall: several firms maintained or raised targets while at least one adjusted its price target (see below). This creates both support and some variability in near-term expectations. Wall Street analyst targets
• Neutral Sentiment: Trading indicators: intraday volume is notably above the stock’s average, which amplifies price moves but can increase short-term volatility. (Background market data)
• Neutral Sentiment: Short‑interest notices in the data feed show anomalous zero/NaN values and a 0.0 days‑to‑cover figure — the data appears unreliable and should be treated cautiously by traders monitoring short activity.
• Negative Sentiment: Wells Fargo trimmed its price target from $93 to $85 despite keeping an Overweight rating, a modest negative signal that reduces the high‑end analyst consensus. Wells Fargo target cut

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.